$ALT
Altimmune Inc Stock $alt

$alt Overview Financials Valuation SEC Filings Company Website

2014 Q3 Form 10-Q Financial Statement

#000114420414046858 Filed on August 05, 2014

Income Statement

Concept	2014 Q3	2014 Q2	2013 Q2
Revenue	$8.00	$676.00	$1.656K
YoY Change	-74.19%	-59.18%	-99.97%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.190M	$2.420M	$2.330M
YoY Change	-22.0%	3.86%	-16.19%
% of Gross Profit
Research & Development	$1.729M	$2.373M	$3.403M
YoY Change	-32.37%	-30.27%	-30.82%
% of Gross Profit
Depreciation & Amortization	$37.13K	$36.21K	$41.85K
YoY Change	-16.75%	-13.49%	-40.21%
% of Gross Profit
Operating Expenses	$4.958M	$4.829M	$5.777M
YoY Change	-25.85%	-16.42%	-25.7%
Operating Profit	-$3.996M	-$1.170M	-$1.482M
YoY Change	24.91%	-21.05%	1.61%
Interest Expense	$46.93K	$56.55K	$100.0K
YoY Change	-47.75%	-43.46%	-10.17%
% of Operating Profit
Other Income/Expense, Net	-$607.3K	$724.1K	$256.6K
YoY Change	-15.4%	182.22%	-64.26%
Pretax Income	-$4.603M	-$445.8K	-$1.225M
YoY Change	17.52%	-63.61%	65.47%
Income Tax	$25.07K	-$10.00K	$11.21K
% Of Pretax Income
Net Earnings	-$4.628M	-$439.1K	-$1.236M
YoY Change	17.3%	-64.48%	63.42%
Net Earnings / Revenue	-57855437.5%	-64958.58%	-74660.14%
Basic Earnings Per Share	-$0.08	-$0.01	-$0.02
Diluted Earnings Per Share	-$0.08	-$0.01	-$0.02
COMMON SHARES
Basic Shares Outstanding	56.44M shares	54.48M shares	49.46M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q3	2014 Q2	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$19.60M	$11.30M	$15.80M
YoY Change	23.27%	-28.48%	33.9%
Cash & Equivalents	$19.62M	$11.27M	$15.79M
Short-Term Investments	$6.400M	$6.400M
Other Short-Term Assets	$700.0K	$600.0K	$700.0K
YoY Change	250.0%	-14.29%	0.0%
Inventory
Prepaid Expenses
Receivables	$300.0K	$600.0K	$5.200M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$20.59M	$12.43M	$21.69M
YoY Change	15.87%	-42.68%	4.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$362.5K	$386.5K	$460.1K
YoY Change	-15.61%	-15.99%	-26.45%
Goodwill	$2.348M	$2.348M	$2.348M
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$53.38K	$55.03K	$85.91K
YoY Change	-28.43%	-35.94%	-42.91%
Total Long-Term Assets	$2.764M	$2.790M	$2.894M
YoY Change	-3.09%	-3.61%	-7.36%
TOTAL ASSETS
Total Short-Term Assets	$20.59M	$12.43M	$21.69M
Total Long-Term Assets	$2.764M	$2.790M	$2.894M
Total Assets	$23.35M	$15.22M	$24.59M
YoY Change	13.24%	-38.08%	3.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$282.0K	$437.4K	$2.993M
YoY Change	-75.67%	-85.38%	45.08%
Accrued Expenses	$2.600M	$1.400M	$2.100M
YoY Change	0.0%	-33.33%	-32.26%
Deferred Revenue
YoY Change
Short-Term Debt			$1.168M
YoY Change
Long-Term Debt Due	$993.3K	$1.000M	$1.000M
YoY Change	-0.67%	0.0%	120.0%
Total Short-Term Liabilities	$3.885M	$2.831M	$7.722M
YoY Change	-28.24%	-63.34%	36.46%
LONG-TERM LIABILITIES
Long-Term Debt		$239.7K	$1.218M
YoY Change		-80.31%	-38.61%
Other Long-Term Liabilities	$507.1K	$572.9K	$577.7K
YoY Change	-14.35%	-0.84%	2.28%
Total Long-Term Liabilities	$507.1K	$812.6K	$1.796M
YoY Change	-67.63%	-54.74%	-29.54%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.885M	$2.831M	$7.722M
Total Long-Term Liabilities	$507.1K	$812.6K	$1.796M
Total Liabilities	$5.244M	$4.359M	$11.37M
YoY Change	-43.4%	-61.65%	10.76%
SHAREHOLDERS EQUITY
Retained Earnings	-$217.7M	-$213.0M	-$202.0M
YoY Change	5.71%	5.48%	2.45%
Common Stock	$236.0M	$224.1M	$215.4M
YoY Change	8.51%	4.04%	2.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$18.11M	$10.86M	$13.22M
YoY Change
Total Liabilities & Shareholders Equity	$23.35M	$15.22M	$24.59M
YoY Change	13.24%	-38.08%	3.27%

Cashflow Statement

Concept	2014 Q3	2014 Q2	2013 Q2
OPERATING ACTIVITIES
Net Income	-$4.628M	-$439.1K	-$1.236M
YoY Change	17.3%	-64.48%	63.42%
Depreciation, Depletion And Amortization	$37.13K	$36.21K	$41.85K
YoY Change	-16.75%	-13.49%	-40.21%
Cash From Operating Activities	-$2.120M	-$540.0K	-$490.0K
YoY Change	211.76%	10.2%	-81.85%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	-$40.00K	-$40.00K
YoY Change	0.0%	0.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$10.00K	-$40.00K	-$40.00K
YoY Change	0.0%	0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.50M	2.300M	3.460M
YoY Change	1150.0%	-33.53%	-527.16%
NET CHANGE
Cash From Operating Activities	-2.120M	-540.0K	-490.0K
Cash From Investing Activities	-10.00K	-40.00K	-40.00K
Cash From Financing Activities	10.50M	2.300M	3.460M
Net Change In Cash	8.370M	1.720M	2.930M
YoY Change	5480.0%	-41.3%	-183.48%
FREE CASH FLOW
Cash From Operating Activities	-$2.120M	-$540.0K	-$490.0K
Capital Expenditures	-$10.00K	-$40.00K	-$40.00K
Free Cash Flow	-$2.110M	-$500.0K	-$450.0K
YoY Change	214.93%	11.11%	-83.33%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Period End Date DocumentPeriodEndDate	2014-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001326190
CY2014Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	56442195	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	PHARMATHENE, INC
	dei	Trading Symbol TradingSymbol	PIP
CY2014Q2	pip	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	1393856	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2013Q4	pip	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	3182687	USD
CY2014Q2	pip	Billed And Unbilled Accounts Receivable Net BilledAndUnbilledAccountsReceivableNet	600000	USD
CY2014Q2	pip	Long Term Debt Excluding Discount LongTermDebtExcludingDiscount	1250005	USD
CY2009Q3	pip	Warrant Expiration Date WarrantExpirationDate	2015-01-28
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	437382	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1128172	USD
CY2014Q2	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-220003	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-218710	USD
CY2014Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	224104547	USD
CY2013Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11700000	shares
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	891983	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	652589	USD
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	363105	USD
CY2013Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	324008	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12300000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11700000	shares
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	217877117	USD
CY2014Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12300000	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52304246	shares
CY2014Q2	us-gaap	Assets Assets	15223483	USD
CY2013Q4	us-gaap	Assets Assets	17139289	USD
CY2014Q2	us-gaap	Assets Current AssetsCurrent	12433457	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	14339108	USD
CY2014Q2	us-gaap	Billed Contract Receivables BilledContractReceivables		USD
CY2013Q4	us-gaap	Billed Contract Receivables BilledContractReceivables	1427113	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11265082	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10480979	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15789909	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12701517	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	784103	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3088392	USD
CY2014Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	5620128	shares
CY2013Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	5620128	shares
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55525710	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52304246	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55525710	shares
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	5553	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	5230	USD
	us-gaap	Contracts Revenue ContractsRevenue	7401458	USD
	us-gaap	Contracts Revenue ContractsRevenue	10770538	USD
CY2014Q2	us-gaap	Contracts Revenue ContractsRevenue	3658933	USD
CY2013Q2	us-gaap	Contracts Revenue ContractsRevenue	4295400	USD
CY2014Q2	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-6668	USD
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	23037	USD
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	20949	USD
CY2013Q2	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	11206	USD
CY2012Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2500000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	23037	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	20949	USD
CY2014Q2	us-gaap	Deferred Revenue DeferredRevenue		USD
CY2013Q4	us-gaap	Deferred Revenue DeferredRevenue	341723	USD
	us-gaap	Depreciation Depreciation	76147	USD
	us-gaap	Depreciation Depreciation	94456	USD
CY2014Q2	us-gaap	Depreciation Depreciation	36208	USD
CY2013Q2	us-gaap	Depreciation Depreciation	41854	USD
CY2014Q2	us-gaap	Derivative Assets DerivativeAssets	6429144	USD
CY2013Q4	us-gaap	Derivative Assets DerivativeAssets	7928807	USD
CY2014Q2	us-gaap	Derivative Instruments And Hedges Liabilities DerivativeInstrumentsAndHedgesLiabilities	4	USD
CY2013Q4	us-gaap	Derivative Instruments And Hedges Liabilities DerivativeInstrumentsAndHedgesLiabilities	51663	USD
CY2014Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	715045	USD
CY2013Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	1740235	USD
CY2013Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	1848566	USD
CY2012Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	1295613	USD
CY2014Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	4	USD
CY2013Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	51663	USD
CY2014Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	715041	USD
CY2013Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1688572	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-1116	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-4080	USD
CY2014Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2100000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M12D
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2419909	USD
CY2013Q4	us-gaap	Goodwill Goodwill	2348453	USD
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2332730	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	5393	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5097361	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4612525	USD
CY2014Q2	us-gaap	Goodwill Goodwill	2348453	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2674523	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3326808	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-445788	USD
CY2014Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	999996	USD
CY2013Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	999996	USD
CY2014Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	750007	USD
CY2014Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	499998	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-419811	USD
	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	682	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1225166	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-690790	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1292796	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1427113	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-892581	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1838131	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-366136	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-341723	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-873580	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	278333	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-355878	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-1582129	USD
	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	2439	USD
CY2014Q2	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	676	USD
CY2013Q2	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	1656	USD
	us-gaap	Interest Expense InterestExpense	127108	USD
	us-gaap	Interest Expense InterestExpense	199818	USD
CY2014Q2	us-gaap	Interest Expense InterestExpense	57230	USD
CY2013Q2	us-gaap	Interest Expense InterestExpense	100027	USD
	us-gaap	Interest Paid InterestPaid	77797	USD
	us-gaap	Interest Paid InterestPaid	129345	USD
CY2014Q2	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	6429144	USD
CY2013Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	7928807	USD
CY2014Q2	us-gaap	Liabilities Liabilities	4358871	USD
CY2013Q4	us-gaap	Liabilities Liabilities	9803577	USD
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15223483	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17139289	USD
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2831238	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6795981	USD
CY2014Q2	us-gaap	Long Term Debt LongTermDebt	1239734	USD
CY2014Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	239738	USD
CY2013Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	730279	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-70581	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2827400	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-234987	USD
	us-gaap	Net Income Loss NetIncomeLoss	-2697560	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3347757	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-439120	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-1236372	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3571737	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2572463	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1169871	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1481729	USD
CY2014Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	55032	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	65660	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3683846	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3398040	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-71227	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	897214	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-754345	USD
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	724083	USD
CY2013Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	256563	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
	us-gaap	Operating Expenses OperatingExpenses	10973195	USD
	us-gaap	Operating Expenses OperatingExpenses	13343001	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	4828804	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	5777129	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1293	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2946	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-636	USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1262	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2698853	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3350703	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-439756	USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1237634	USD
CY2014Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	572854	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	588745	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1550	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4013	USD
CY2014Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1912	USD
CY2013Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2110	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	49311	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	70473	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	79227	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	70581	USD
CY2014Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	550979	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	231491	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5275584	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3810403	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-1091740	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-162364	USD
	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt	-499998	USD
	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt	-249999	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	8000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		USD
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	386541	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	386068	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5799687	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8636020	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2372687	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3402545	USD
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-213025485	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-210327925	USD
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	49749167	shares
	us-gaap	Share Based Compensation ShareBasedCompensation	891983	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	652589	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1357755	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	205000	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	140000	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	145000	shares
CY2014Q2	us-gaap	Short Term Borrowings ShortTermBorrowings		USD
CY2013Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	1091740	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	10864612	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	7335712	USD
CY2014Q2	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	617396	USD
CY2013Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	2199525	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	1025190	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-552953	USD
CY2014Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	782549	USD
CY2013Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	352824	USD
	us-gaap	Use Of Estimates UseOfEstimates	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <em>Use of Estimates</em></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">  </p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period.  Our unaudited condensed consolidated financial statements include significant estimates for our share-based compensation and the value of our financial instruments, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">  </p> <!--EndFragment--></div> </div>
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	53861988	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	49058014	shares
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54670870	shares

Files In Submission

Name	View Source	Status
0001144204-14-046858-index-headers.html	Edgar Link	pending
0001144204-14-046858-index.html	Edgar Link	pending
0001144204-14-046858.txt	Edgar Link	pending
0001144204-14-046858-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
pip-20140630.xml	Edgar Link	completed
pip-20140630.xsd	Edgar Link	pending
pip-20140630_cal.xml	Edgar Link	unprocessable
pip-20140630_def.xml	Edgar Link	unprocessable
pip-20140630_lab.xml	Edgar Link	unprocessable
pip-20140630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v384490_10q.htm	Edgar Link	pending
v384490_ex31-1.htm	Edgar Link	pending
v384490_ex31-2.htm	Edgar Link	pending
v384490_ex32-1.htm	Edgar Link	pending
v384490_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALT
Altimmune Inc Stock $alt

2014 Q3 Form 10-Q Financial Statement

#000114420414046858 Filed on August 05, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALT Altimmune Inc Stock $alt

2014 Q3 Form 10-Q Financial Statement

#000114420414046858 Filed on August 05, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALT
Altimmune Inc Stock $alt